Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Business

Tagomics Secures £6.7 Million to Enhance Disease Diagnosis Technology

by February 21, 2024
February 21, 2024
Tagomics Secures £6.7 Million to Enhance Disease Diagnosis Technology

Tagomics, a trailblazing developer of a state-of-the-art platform for comprehensive disease insight and diagnosis, has announced a successful £6.7 million funding round.

This milestone comes on the heels of a £1.6 million pre-seed round led by IQ Capital and Start Codon, supplemented by grant funding from Innovate UK.

The infusion of capital will expedite Tagomics’ scientific research and product development endeavors, aimed at advancing the diagnosis and treatment of various diseases, including cancer. The funding round was spearheaded by Calculus Capital, with participation from prominent investors such as Illumina Ventures, IQ Capital, Agilent Ventures, Mercia Ventures, MEIF Proof of Concept & Early Stage Fund (managed by Mercia Ventures), Meltwind, and OMX Ventures.

Established in July 2020 as a spin-out from the University of Birmingham, Tagomics builds upon pioneering research spearheaded by Dr. Robert Neely, the company’s Chief Scientific Officer. Tagomics has crafted a groundbreaking platform that seamlessly integrates multiple “omics” technologies, including genomics, epigenomics, and fragmentomics, to offer a holistic understanding of human health and disease. By leveraging advanced data analysis and machine learning, Tagomics aims to unearth new disease markers, foster strategic partnerships, and advance drug development and therapy selection.

Since securing investment, Tagomics has secured the distinction of becoming the inaugural tenant of Illumina Ventures’ Labs in Cambridge. This facility provides invaluable resources and support to genomics startups, facilitating their growth trajectory from inception to Series A financings.

Dr. Jack Kennefick, CEO and Co-founder of Tagomics, expressed optimism about the company’s trajectory, highlighting the transformative potential of its multiomic approach in enhancing disease diagnosis and treatment. Elizabeth Klein, Investment Director at Calculus, commended Tagomics’ innovative technology and exceptional leadership team, emphasizing CEO Dr. Jack Kennefick’s expertise and the collective experience of the board members.

Nick Naclerio, Founding Partner at Illumina Ventures, underscored the significance of Tagomics’ inclusion in Illumina Ventures Labs, expressing confidence in the collaborative efforts to expedite the company’s market penetration.

As Tagomics embarks on its next phase of expansion, buoyed by robust investor support and cutting-edge technology, it aims to redefine the landscape of genomic medicine, offering novel insights and solutions to address critical healthcare challenges.

It’s noteworthy that the Midlands Engine Investment Fund, which supported Tagomics’ growth, will soon transition to Midlands Engine Investment Fund II, marking a new chapter in fostering innovation and economic development in the region.

Read more:
Tagomics Secures £6.7 Million to Enhance Disease Diagnosis Technology

0
FacebookTwitterGoogle +Pinterest
previous post
State Department says ‘major sanctions package’ coming to hold Russia ‘accountable for Navalny’s death’
next post
Setting Standards: Harambe Token’s Legacy

You may also like

Getting to Know You: Daniel Mackle, Founder of...

May 31, 2023

Trading Digitally: Understanding The Regulatory Requirements For Selling...

May 7, 2024

Apple announces new security and privacy measures amid...

December 8, 2022

5 Essential Water Truck Parts for Every Fleet...

August 10, 2024

Business Leaders Fear Legal Action Over ESG Targets

February 29, 2024

Cost of living crisis hits ‘zombie’ companies

August 2, 2023

The Rise of Online Gambling: Opportunities for Tech...

January 3, 2025

FTSE 100 ends year up 3.8% but trails...

December 30, 2023

Large businesses take more space in London

February 1, 2024

The Future of AI Translation: Why User-Driven Customization...

February 17, 2025

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Rubio condemns assassination attempt on Colombian presidential candidate Miguel Uribe

      June 8, 2025
    • Obama WH physician says Biden doc should have performed cognitive test

      June 8, 2025
    • Trump warns of ‘serious consequences’ if Elon Musk funds Democrats

      June 7, 2025
    • Musk jokes about reconsidering stance on Big Beautiful Bill after Schiff’s praise

      June 7, 2025
    • Musk deletes explosive posts about Trump and Epstein files

      June 7, 2025
    • House witness flips script on Dem who ambushed him during hearing with unearthed tweet: ‘Iceberg is ahead’

      June 7, 2025

    Categories

    • Business (8,152)
    • Investing (2,019)
    • Politics (15,570)
    • Stocks (3,136)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved